TTBK1-IN-4
TTBK1-IN-4 (Compound 19) is a potent inhibitor of TTBK1, with a biochemical IC₅₀ of 2.3 nM and a cellular IC₅₀ of 42 nM. TTBK1-IN-4 can be used for research on Alzheimer's disease.
For research use only. We do not sell to patients.
- CAS No.: 2735015-54-8
- Formula: C17H17N5O
- Molecular Weight:307.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
TTBK1 2.3 nM () |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
0.054 μM
Compound: 19
|
Cytotoxicity against human HepG2 cells in glucose containing media incubated for 72 hrs by celltiter-glo luminescent cell viability assay
Cytotoxicity against human HepG2 cells in glucose containing media incubated for 72 hrs by celltiter-glo luminescent cell viability assay
|
[PMID: 33944571] |
| HepG2 | IC50 |
0.12 μM
Compound: 19
|
Cytotoxicity against human HepG2 cells in galactose containing media incubated for 72 hrs by celltiter-glo luminescent cell viability assay
Cytotoxicity against human HepG2 cells in galactose containing media incubated for 72 hrs by celltiter-glo luminescent cell viability assay
|
[PMID: 33944571] |
Chemical Information
-
CAS No. 2735015-54-8
-
Molecular Weight 307.35
-
Formula C17H17N5O
-
SMILES
CC[C@](C)(O)C#CC1=NC=C2C=CN(C3=NC(N)=NC=C3)C2=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)